4imk
From Proteopedia
(Difference between revisions)
| (4 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{STRUCTURE_4imk| PDB=4imk | SCENE= }} | ||
| - | ===Uncrossed Fab binding to human Angiopoietin 2=== | ||
| - | {{ABSTRACT_PUBMED_23613981}} | ||
| - | == | + | ==Uncrossed Fab binding to human Angiopoietin 2== |
| - | [[4imk]] is a 4 chain structure with sequence from [ | + | <StructureSection load='4imk' size='340' side='right'caption='[[4imk]], [[Resolution|resolution]] 2.20Å' scene=''> |
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4imk]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4IMK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4IMK FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.202Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4imk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4imk OCA], [https://pdbe.org/4imk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4imk RCSB], [https://www.ebi.ac.uk/pdbsum/4imk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4imk ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action. There is a wide variety of design alternatives for such bispecific antibodies, including the "CrossMab" format. CrossMabs contain a domain crossover in one of the antigen-binding (Fab) parts, together with the "knobs-and-holes" approach, to enforce the correct assembly of four different polypeptide chains into an IgG-like bispecific antibody. We determined the crystal structure of a hAng-2-binding Fab in its crossed and uncrossed form and show that CH1-CL-domain crossover does not induce significant perturbations of the structure and has no detectable influence on target binding. | ||
| - | + | Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain.,Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, Moelleken J, Regula JT, Schaefer W, Thomas M, Klein C, Hopfner KP, Kettenberger H PLoS One. 2013 Apr 17;8(4):e61953. doi: 10.1371/journal.pone.0061953. Print 2013. PMID:23613981<ref>PMID:23613981</ref> | |
| - | <ref | + | |
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 4imk" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| - | [[Category: Fenn | + | [[Category: Large Structures]] |
| - | [[Category: Griese | + | [[Category: Fenn S]] |
| - | [[Category: Hopfner | + | [[Category: Griese JJ]] |
| - | [[Category: Kettenberger | + | [[Category: Hopfner K-P]] |
| - | [[Category: Schiller | + | [[Category: Kettenberger H]] |
| - | + | [[Category: Schiller C]] | |
| - | + | ||
Current revision
Uncrossed Fab binding to human Angiopoietin 2
| |||||||||||
